Cytek Biosciences (CTKB)
(Real Time Quote from BATS)
$6.14 USD
+0.04 (0.66%)
Updated May 16, 2024 12:10 PM ET
2-Buy of 5 2
C Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CTKB 6.14 +0.04(0.66%)
Will CTKB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CTKB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTKB
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
CTKB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
Cytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?
Cytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CTKB
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Cytek Biosciences price target lowered by $1.50 at Piper Sandler, here's why
Cytek Biosciences (CTKB) Gets a Buy from Piper Sandler
Cytek Biosciences, Inc. (CTKB) Q1 2024 Earnings Call Transcript
Cytek Biosciences Inc (CTKB) Q1 2024 Earnings: Revenue Surges, Yet Net Loss Persists